Primary Myelofibrosis (PMF): Clinical Trials

7 trials for Primary Myelofibrosis (PMF), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 unknown, 1 recruiting. 7 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Unknown 2, Recruiting 1
Phase 12Completed 2
Phase 31Unknown 1

Follow Primary Myelofibrosis (PMF): new trials by email Literature Review of Primary Myelofibrosis (PMF) trials Research Report on Primary Myelofibrosis (PMF)

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Ropeginterferon alfa-2b (BESREMi®) - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Phase 2RecruitingThe University of Hong Kong202025-03-012025-06-11
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
KRT-232, TL-895 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Phase 2UnknownKartos Therapeutics, Inc.522021-04-132022-05-09
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
PXS-5505 - Myelofibrosis, Primary Myelofibrosis (PMF)
Phase 1 / Phase 2CompletedSyntara432021-02-182026-08-04
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Jaktinib hydrochloride tablets - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF)
Phase 2CompletedSuzhou Zelgen Biopharmaceuticals Co.,Ltd512020-01-072023-04-20
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF)
Phase 2 / Phase 3UnknownKartos Therapeutics, Inc.3852019-01-152023-04-28
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
Bomedemstat - Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF)
Phase 1 / Phase 2CompletedImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)902017-07-182024-01-10
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
MMB - Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis
Phase 2CompletedSierra Oncology LLC - a GSK company412016-01-292023-06-18

Narrower conditions

Primary Myelofibrosis (7)

Broader conditions

Bone Marrow Diseases (7)  ·  Hematologic Diseases (7)  ·  Hemic and Lymphatic Diseases (7)  ·  Myeloproliferative Disorders (7)

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2)  ·  N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (1)  ·  bomedemstat (1)

Sponsors

Kartos Therapeutics, Inc. (2)  ·  Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (1)  ·  Sierra Oncology LLC - a GSK company (1)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)  ·  Syntara (1)  ·  The University of Hong Kong (1)

Countries

United States (5)  ·  Australia (3)  ·  Bulgaria (2)  ·  Canada (2)  ·  Germany (2)  ·  Hong Kong (2)  ·  Italy (2)  ·  Mexico (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Belarus (1)

Top investigators

Harinder Gill, MD (1)  ·  Jana Baskar, MBBS MMedSc MBA (1)  ·  Jie Jin, MD (1)

Results publications

PMID 39516087, PMID 40241543, PMID 41758981, PMID 42054549

NIH funding

2018 (1)